


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8399161/publications.pdf Version: 2024-02-01



DANI REDCÃO

#	Article	IF	CITATIONS
1	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophrenia Research, 2015, 164, 65-73.	2.0	92
2	Abnormal P300 in people with high risk of developing psychosis. NeuroImage, 2008, 41, 553-560.	4.2	87
3	Gray matter volume deficits and correlation with insight and negative symptoms in first-psychotic-episode subjects. Acta Psychiatrica Scandinavica, 2011, 123, 431-439.	4.5	81
4	Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study. Psychiatric Services, 2016, 67, 227-233.	2.0	69
5	Neural correlates of impaired emotional discrimination in borderline personality disorder: An fMRI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1537-1545.	4.8	61
6	Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis. Schizophrenia Bulletin, 2016, 42, 344-357.	4.3	58
7	Spanish adaptation and validation of the Brief Negative Symptoms Scale. Comprehensive Psychiatry, 2014, 55, 1726-1729.	3.1	54
8	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research, 2017, 189, 84-90.	2.0	49
9	Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Research, 2015, 229, 70-74.	3.3	43
10	A 12-month study of the hikikomori syndrome of social withdrawal: Clinical characterization and different subtypes proposal. Psychiatry Research, 2018, 270, 1039-1046.	3.3	42
11	The relationship between frequency and intensity of fears and a collagen condition. Depression and Anxiety, 2006, 23, 412-417.	4.1	29
12	Default Mode Network Aberrant Connectivity Associated with Neurological Soft Signs in Schizophrenia Patients and Unaffected Relatives. Frontiers in Psychiatry, 2017, 8, 298.	2.6	29
13	Cannabis use, COMT, BDNF and age at first-episode psychosis. Psychiatry Research, 2017, 250, 38-43.	3.3	26
14	Affective versus non-affective first episode psychoses: A longitudinal study. Journal of Affective Disorders, 2018, 238, 297-304.	4.1	26
15	Family Features of Social Withdrawal Syndrome (Hikikomori). Frontiers in Psychiatry, 2020, 11, 138.	2.6	25
16	Dual Diagnosis in an Inpatient Drug-Abuse Detoxification Unit. European Addiction Research, 2007, 13, 192-200.	2.4	18
17	Limbic activity in antipsychotic naÃ <sup>-</sup> ve first-episode psychotic subjects during facial emotion discrimination. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 271-283.	3.2	18
18	The negative syndrome of schizophrenia: Three -underlying components are better than two. Schizophrenia Research, 2015, 166, 115-118.	2.0	18

Dani Bergé

#	Article	IF	CITATIONS
19	Obstetric Phenotypes in the Heterogeneity of Schizophrenia. Journal of Nervous and Mental Disease, 2018, 206, 882-886.	1.0	18
20	The impact of sex and cannabis on clinical features in first–admitted patients with psychosis. European Neuropsychopharmacology, 2020, 36, 235-243.	0.7	15
21	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. Journal of Clinical Medicine, 2021, 10, 73.	2.4	14
22	Smoking does not impact social and non-social cognition in patients with first episode psychosis. Schizophrenia Research, 2018, 199, 64-74.	2.0	13
23	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 164-176.	1.8	13
24	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. European Neuropsychopharmacology, 2021, 49, 54-68.	0.7	12
25	Onset of Mania After CPAP in a Man With Obstructive Sleep Apnea. Psychosomatics, 2008, 49, 447-449.	2.5	11
26	Schizophrenia, antipsychotic drugs and cardiovascular risk: Descriptive study in primary care. European Psychiatry, 2015, 30, 535-541.	0.2	11
27	Increased nucleus accumbens volume in first-episode psychosis. Psychiatry Research - Neuroimaging, 2017, 263, 57-60.	1.8	11
28	Cognitive clusters in first-episode psychosis. Schizophrenia Research, 2021, 237, 31-39.	2.0	10
29	Improvement in prefrontal thalamic connectivity during the early course of the illness in recent-onset psychosis: a 12-month longitudinal follow-up resting-state fMRI study. Psychological Medicine, 2022, 52, 2713-2721.	4.5	10
30	Association between neurological soft signs, temperament and character in patients with schizophrenia and non-psychotic relatives. PeerJ, 2016, 4, e1651.	2.0	10
31	Reduced willingness to invest effort in schizophrenia with high negative symptoms regardless of reward stimulus presentation and reward value. Comprehensive Psychiatry, 2018, 87, 153-160.	3.1	8
32	Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis. Schizophrenia Research, 2020, 223, 345-352.	2.0	8
33	The Neuroanatomical Basis of Panic Disorder and Social Phobia in Schizophrenia: A Voxel Based Morphometric Study. PLoS ONE, 2015, 10, e0119847.	2.5	6
34	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. Schizophrenia Research, 2020, 218, 292-294.	2.0	6
35	Influence of secondary sources in the Brief Negative Symptom Scale. Schizophrenia Research, 2019, 204, 452-454.	2.0	5
36	Dificultades en el parto y sintomatologÃa depresiva en la esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 66-68.	1.8	5

Dani Bergé

#	Article	IF	CITATIONS
37	Multidimensional predictors of negative symptoms in antipsychotic-naive first-episode psychosis. Journal of Psychiatry and Neuroscience, 2022, 47, E21-E31.	2.4	5
38	Patient Management and Psychopharmacological Treatment Associated to Smoking Ban in an Acute Psychiatric Unit. Community Mental Health Journal, 2015, 51, 746-752.	2.0	4
39	Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 647-659.	3.2	3
40	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 164-176.	0.3	3
41	Social withdrawal and suicide risk: A descriptive study. European Psychiatry, 2016, 33, S175-S175.	0.2	1
42	WC5G NEUROPHYSIOLOGIC MARKERS OF RISK OF DEVELOPING PSYCHOSIS. Schizophrenia Research, 2006, 86, S14.	2.0	0
43	Diagnostic Stability and Clinical Characteristics in First-episode Psychosis. European Psychiatry, 2009, 24, .	0.2	0
44	Poster #189 PREDICTION OF RELAPSE AFTER A FIRST EPISODE OF PSYCHOSIS: A FOLLOW-UP CLINICAL STUDY. Schizophrenia Research, 2012, 136, S159.	2.0	0
45	P.3.b.035 Temperament, character and neurological soft signs in patients with schizophrenia and unaffected siblings. European Neuropsychopharmacology, 2013, 23, S450.	0.7	0
46	P.3.f.015 Abnormal functioning of the default mode network in schizophrenia and unaffected relatives: a study of functional magnetic resonance. European Neuropsychopharmacology, 2013, 23, S500-S501.	0.7	0
47	P.3.b.002 Cortex morphology and subcortical brain grey matter deficits in schizophrenia and unaffected relatives. European Neuropsychopharmacology, 2015, 25, S463-S464.	0.7	0
48	Effort-based reward task, a behavioral measure to study negative symptoms in schizophrenia. European Psychiatry, 2017, 41, S343-S344.	0.2	0